Literature DB >> 20926112

Influence of an additional amino group on the potency of aminoadamantanes against influenza virus A. II - Synthesis of spiropiperazines and in vitro activity against influenza A H3N2 virus.

Christos Fytas1, Antonios Kolocouris, George Fytas, Grigoris Zoidis, Charalampos Valmas, Christopher F Basler.   

Abstract

Spiro[piperidine-2,2'-adamantane] 4 is one of the most potent synthetic anti-influenza A aminoadamantanes or other cage structure amines tested so far. Based on previous results Tataridis et al. (2007) [5h] which demonstrate the boost of in vitro potency by the presence of an additional amino group, we examined whether the incorporation of a second amino group into this heterocycle would increase the anti-influenza A virus activity. The new synthetic molecules 5-7 are capable of forming two hydrogen bonds within the receptor. We identified the diamino derivatives 5 and 6, which are active against influenza A H3N2 virus although less potent than amantadine and its equipotent spiropiperidine 4.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926112      PMCID: PMC2997423          DOI: 10.1016/j.bioorg.2010.09.001

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  27 in total

Review 1.  Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.

Authors:  R P Mason; D G Rhodes; L G Herbette
Journal:  J Med Chem       Date:  1991-03       Impact factor: 7.446

2.  Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block.

Authors:  C Wang; K Takeuchi; L H Pinto; R A Lamb
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

3.  Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.

Authors:  N Kolocouris; A Kolocouris; G B Foscolos; G Fytas; J Neyts; E Padalko; J Balzarini; R Snoeck; G Andrei; E De Clercq
Journal:  J Med Chem       Date:  1996-08-16       Impact factor: 7.446

4.  Synthesis of substituted 1-norbornylamines with antiviral activity.

Authors:  A García Martínez; E Teso Vilar; A García Fraile; S de la Moya Cerero; M E Rodríguez Herrero; P Martínez Ruiz; L R Subramanian; A García Gancedo
Journal:  J Med Chem       Date:  1995-10-27       Impact factor: 7.446

5.  Maturation of influenza A virus hemagglutinin--estimates of the pH encountered during transport and its regulation by the M2 protein.

Authors:  S Grambas; A J Hay
Journal:  Virology       Date:  1992-09       Impact factor: 3.616

6.  Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells.

Authors:  I V Chizhmakov; F M Geraghty; D C Ogden; A Hayhurst; M Antoniou; A J Hay
Journal:  J Physiol       Date:  1996-07-15       Impact factor: 5.182

7.  Influenza virus M2 protein has ion channel activity.

Authors:  L H Pinto; L J Holsinger; R A Lamb
Journal:  Cell       Date:  1992-05-01       Impact factor: 41.582

8.  Neutron diffraction reveals the site of amantadine blockade in the influenza A M2 ion channel.

Authors:  K C Duff; P J Gilchrist; A M Saxena; J P Bradshaw
Journal:  Virology       Date:  1994-07       Impact factor: 3.616

9.  Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.

Authors:  N Kolocouris; G B Foscolos; A Kolocouris; P Marakos; N Pouli; G Fytas; S Ikeda; E De Clercq
Journal:  J Med Chem       Date:  1994-09-02       Impact factor: 7.446

10.  The molecular basis of the specific anti-influenza action of amantadine.

Authors:  A J Hay; A J Wolstenholme; J J Skehel; M H Smith
Journal:  EMBO J       Date:  1985-11       Impact factor: 11.598

View more
  3 in total

1.  Heterocyclic Inhibitors of Viroporins in the Design of Antiviral Compounds.

Authors:  Vadim A Shiryaev; Yuri N Klimochkin
Journal:  Chem Heterocycl Compd (N Y)       Date:  2020-07-17       Impact factor: 1.277

Review 2.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

Review 3.  Progress of small molecular inhibitors in the development of anti-influenza virus agents.

Authors:  Xiaoai Wu; Xiuli Wu; Qizheng Sun; Chunhui Zhang; Shengyong Yang; Lin Li; Zhiyun Jia
Journal:  Theranostics       Date:  2017-02-08       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.